Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised Prostate Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Repository.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Reirradiation Options for Previously Irradiated Prostate Cancer: Is It Feasible to Randomise Between Treatment With Stereotactic Body Radiotherapy (SBRT) Versus High-Dose-Rate Brachytherapy?

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Unravelling Salvage Re-irradiation for Locally Recurrent Prostate Cancer: Challenges and Complexities.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Enriching African genome representation through the AGenDA project.

Nature·2026

Related Experiment Video

Updated: Nov 11, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.1K

Hypoxia and its Modification in Bladder Cancer: Current and Future Perspectives.

T Lodhi1, Y P Song1, C West2

  • 1Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 25, 2021
PubMed
Summary
This summary is machine-generated.

Hypoxia in muscle-invasive bladder cancer (MIBC) hinders radiotherapy effectiveness. Identifying hypoxic tumors using biomarkers like mRNA signatures can guide treatment selection for improved patient survival.

Keywords:
Bladder cancerHIFgene mRNA signaturehypoxiaradiosensitiserradiotherapy

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.8K
Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
08:15

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

16.2K

Related Experiment Videos

Last Updated: Nov 11, 2025

Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

5.1K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.8K
Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
08:15

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

16.2K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Molecular Biology

Background:

  • Muscle-invasive bladder cancer (MIBC) treatment relies heavily on radiotherapy.
  • Tumor hypoxia in MIBC negatively impacts radiotherapy response, promoting genetic instability, metastasis, and poorer prognosis.

Purpose of the Study:

  • To review the role of hypoxia in MIBC radiotherapy and discuss identification methods and therapeutic strategies.
  • To highlight the potential of novel biomarkers and emerging therapies for improving outcomes in MIBC.

Main Methods:

  • Review of current literature on hypoxia in MIBC.
  • Discussion of diagnostic markers including histopathology (necrosis), protein expression (HIF-1α, GLUT-1, CAIX), microRNAs, and mRNA signatures.
  • Evaluation of established (carbogen, nicotinamide) and novel therapeutic approaches.

Main Results:

  • Hypoxia is a critical factor limiting radiocurability and survival in MIBC.
  • Various biomarkers show promise for identifying hypoxic tumors, with mRNA signatures being a key area for future clinical integration.
  • Carbogen and nicotinamide remain a gold standard for hypoxia modification, improving survival without significant toxicity.

Conclusions:

  • Accurate identification of hypoxia in MIBC is crucial for treatment stratification and enhancing patient survival.
  • Emerging therapies including bioreductive agents, oxygen delivery systems, immunotherapy, and PARP inhibitors represent future directions.
  • Biomarker-guided interventional trials are essential for optimizing radiotherapy and improving outcomes for MIBC patients.